T1	Participants 95 132	for advanced myeloid leukemia and MDS
T2	Participants 848 941	in patients with myeloid leukemia undergoing allogeneic stem cell transplantation (allo-SCT).
T3	Participants 1321 1325	10%.
T4	Participants 1326 1363	Fifty-one patients have been enrolled
T5	Participants 1403 1408	days.
T6	Participants 1409 1489	There were 32 males and 19 females, with a median age of 45 years (range: 6-59).
T7	Participants 1490 1631	Nine patients had chronic myeloid leukemia (CML) (BC: 2, second AP: 3, and tyrosine-kinase inhibitor refractory first chronic phase [CP]: 4).
T8	Participants 1632 1909	Forty-two patients had AML: 14 were induction failures, 8 in first chemotherapy-refractory relapse, 7 in untreated relapse, 3 in second or subsequent relapse, 4 were in second complete remission (CR), and 3 in second CR without platelet recovery (CRp), 2 were in high-risk CR1.
T9	Participants 1910 1945	Finally, 1 patient was in first CRp
T10	Participants 2158 2168	engrafted.
T11	Participants 2169 2250	Forty-one patients had active leukemia at the time of transplant, and 35 achieved
T12	Participants 2254 2259	(85%)
T13	Participants 2803 2847	safe in high-risk myeloid leukemia patients;
